R&D program on inflammation and its resolution
Ambiotis is the first CRO worldwide specializing in the process OF resolution.
Inflammation is a common host response to injury, irritation or infection.
The process is divided into 3 main steps: onset or initiation, amplification and resolution.
When correctly controlled, inflammation is supposed to end and lead to the complete restoration of the targeted tissue.
Various cell and biochemical effectors from in particular innate and adaptive system are indeed involved throughout the process and are tightly regulated.
The metabolization of pro-inflammatory mediators into inactive compounds is not sufficient to allow the tissue to come back to initial state.
Over the last decade, it has been shown that specific mediators are actually secreted in a timely coordinated manner all along the inflammatory response, including resolution phase.
Resolution is an active process, involving specific mediators that are biologically active and that CAN be used as biomarkers of homeostasis.
These biomarkers are issued from the omega-6 and the omega-3 polyunsaturated fatty acid (PUFA) metabolism and are termed lipoxins, resolvins, maresins and protectins, which are collectively referred to as SPMs (Specialized Pro-resolving Mediators)
Those molecules control physiological mechanisms involved in the end of the inflammatory process from the decrease of inflammatory cell recruitment, the elimination of pathogens and cell debris to the healing of the tissue and the decrease of pain. This offers promising perspectives for new drug development applications against chronic inflammatory diseases.
Indeed, a new branch of pharmacology has recently emerged: resolution pharmacology. Inflammation pharmacology aims at inhibiting mediators that are responsible for bad effects on tissues. By contrast resolution pharmacology focuses on the activation, the increase or improvement of cellular processes involved in the return to initial state (limit/repair damages, clean inflammatory site from debris…)
« The mapping of new resolution circuits has opened the possibility for understanding mechanisms that lead from acute to chronic inflammation, or to the resolution thereof, as well as to potential, resolution-based immunopharmacological therapies. »
(Serhan CN, Am J Pathol 2010)
« In the past decade, a new paradigm in our understanding of the inflammatory process has emerged with the appreciation of genetic, molecular, and cellular mechanisms that are engaged to actively resolve inflammation. The ‘resolution of acute inflammation’ is enabled by counter-regulatory checkpoints to terminate the inflammatory reaction, promoting healing and repair. It may be possible to harness this knowledge for innovative approaches to the treatment of inflammatory pathologies. Here we discuss current translational attempts to develop agonists at proresolving targets as a strategy to rectify chronic inflammatory status. We reason this new approach will lead to the identification of better drugs that will establish a new branch of pharmacology, ‘resolution pharmacology’ »
(Perretti M, Trends in Pharmacological Science,2015)
« it has been proposed that some diseases that are associated with chronic inflam mation may be underpinned by dysregulated resolution as much as driven by ongoing proinflammatory processes, and that therapy based on rectifying these defects will help to guide ongoing inflammation down a proresolution pathway. »
(Fullerton JM, Nature Rev Drug discovery, 2016)
Become a partner : our commitment is to make our innovations your future development
Since its creation, Ambiotis leads R&D programs and investigate the naturally occurring mechanisms involved in the end of the inflammatory process in the aim of favouring them thanks to new molecules.
The company has thus built a thorough experience and expertise in this area to be able to propose finely tuned models in tight concomitance with a robust analytical approach.
The Natural Combination Medicine Traumeel (Tr14) Improves Resolution of Inflammation by Promoting the Biosynthesis of Specialized Pro-Resolving Mediators.
Paul M. Jordan, Emeline van Goethem, Andrea M. Müller, Kathrin Hemmer, Virginie Gavioli, Vincent Baillif, Yvonne Burmeister, Natascha Krömmelbein, Marc Dubourdeau, Bernd Seilheimer and Oliver Werz. Pharmaceuticals 2021 Nov
Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution.
C Trilleaud, V Gauttier, K Biteau, I Girault, L Belarif, C Mary, S Pengam, G Teppaz, V Thepenier, R Danger, G Robert-Siegwald, M Néel, S Bruneau, A Glémain, A Néel, A Poupon, J F Mosnier, G Chêne, M Dubourdeau, G Blancho, B Vanhove, N Poirier. Science Advances, 2021 Apr
The Atlas of Inflammation Resolution.
Charles N Serhan, Shailendra K Gupta, Mauro Perretti, Catherine Godson, Eoin Brennan, Yongsheng Li, Oliver Soehnlein, Takao Shimizu, Oliver Werz, Valerio Chiurchiù, Angelo Azzi, Marc Dubourdeau, Suchi Smita Gupta, Patrick Schopohl, Matti Hoch, Dragana Gjorgevikj, Faiz M Khan, David Brauer, Anurag Tripathi, Konstantin Cesnulevicius, David Lescheid, Myron Schultz, Eva Särndahl, Dirk Repsilber, Robert Kruse, Angelo Sala, Jesper Z Haeggström, Bruce D Levy, János G Filep, Olaf Wolkenhauer. Mol. Aspects Med., 2020 Aug
Resolvin D1 reduces lung infection and inflammation activating resolution in cystic fibrosis.
Domenico Mattoscio, Elisa Isopi, Marilina Codagnone, Veronica Cecilia Mari, Alessia Lamolinara, Marco D'Aurora, Eleonora Cianci, Annalisa Nespoli, Sara Franchi, Valentina Gatta, Marc Dubourdeau, Paolo Moretti, Maria Di Sabatino, Manuela Iezzi, Mario Romano, Antonio Recchiuti. Front. Immunol., 28 April 2020
Differential Profile of Proinflammatory/Proresolving Lipid Mediators in Acute Inflammation Model using Young and Old Skin Biopsies.
Lopez-Gaydon Amandine , Baillif Vincent , Bertholon Cindy , Van Goethem Emeline , Demarne Frédéric , Dubourdeau Marc and Bechetoille Nicolas. Dermatol Res. 2019; 1(1); 1-2
Long chain fatty acids and related pro-inflammatory, specialized pro-resolving lipid mediators and their intermediates in preterm human milk during the first month of lactation.
Robinson DT, Palac HL, Baillif V, Van Goethem E, Dubourdeau M, Van Horn L, Martin CR.- Prostaglandins Leukot Essent Fatty Acids. 2017 Jun - PMID: 28651692
In Vitro and in Vivo Anti-Inflammatory Effect of a Biotechnologically Modified Borage Seed Extract: Evidence for Lipid Pro-Resolving Mediators’ Implication in the Enhancement of Psoriatic and Atopic Dermatitis Lesions
Chene G, Baillif V, Van Goethem E, et al - JCDSA -2015 - DOI: 10.4236/jcdsa.2015.52018
A role for 12/15-lipoxygenase-derived proresolving mediators in postoperative ileus: protectin DX-regulated neutrophil extravasation.
Stein K, Stoffels M, Lysson M, Schneiker B, Dewald O, Krönke G, Kalff JC, Wehner S. - J Leukoc Biol. 2015 Aug 20. PMID: 2629297
Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome.
Cenac N,..., Dubourdeau M,et al. - Gastroenterology. 2015 Apr 21. PMID: 25911511
Molecular and cellular profiles of the resolution phase in a damage-associated molecular pattern-mediated peritonitis model and revelation of leukocyte persistence in peritoneal tissues.
Lastrucci C, Baillif V, ..., Dubourdeau M, et al. FASEB J. 2015 Jan 21. PMID: 25609430
Protective effects of n-6 fatty acids-enriched diet on intestinal ischaemia/reperfusion injury involve lipoxin A4 and its receptor.
Gobbetti T, ..., Dubourdeau M, et al. - Br J Pharmacol. 2015 Feb; PMID: 25296998
Polyunsaturated fatty acid metabolism signature in ischemia differs from reperfusion in mouse intestine.
Gobbetti T, ..., Dubourdeau M, et al. - PLoS One. 2013 Sep 20 PMID: 24073272
LC-MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites.
Le Faouder P, Baillif V, ..., Chêne G, Guigné C, ..., Dubourdeau M, et al. - J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Aug PMID: 23831705
Relevance of the cyclophosphamide-induced cystitis model for pharmacological studies targeting inflammation and pain of the bladder.
Augé C, Chene G, Dubourdeau M, et al. - Eur J Pharmacol. 2013 May 5 PMID: 23541724
From cells to cytokines to health: PNI in translation (co-authorship with Larissa C. Engert, PhD, Harvard Medical School, Sleep and Inflammatory Systems Laboratory) (PNIRS virtual meeting)
Biogenic Synthesis of RvD6 and its Quantification in Skin Biospsies - A Strategy for Analyzing Unavailable but Relevant Biomolecules (Lipids and Cosmetics meeting)
Differential Profiles Of Pro-Inflammatory And Specialized Pro-Resolving Lipid Mediators In PMA-Treated Skin Biopsies From Young And Old Donors (co-authorship with Gattefossé) (IID)
A multicomponent medication promotes inflammation resolution (co-authorship with Biologische Heilmittel Heel GmbH) (NYAS Meeting)
Circadian rythms modulation of senescent skin fibroblasts and impact on the biological functions (co-authorship with Laboratoires Clarins) (SPIM)
Inducing resolution of inflammation to improve skin defense against external aggressions (47th Annual ESDR Meeting)
Resolution of pollution-induced inflammation as an innovative approach for cosmetic actives (COMET)
Monitoring of Pneumocystis jirovecii acquired pneumonia by specialized pro-resolving mediators (World Congress on Inflammation)
Beta Glucans Are Reinforcing the Immune System Through the Mobilization of Resolution Pathways (International Scientific Conference on Probiotics and Prebiotics)
Long chain fatty acids and their related oxylipins in preterm human milk during the first month of lactation (Collaborative work with Daniel T Robinson from Northwestern University Feinberg School of Medicine, Chicago, US) (6th European Workshop on Lipid Mediators)
Glutaminyl cylase (QC) inhibition in a mouse peritonitis model effects eosinophil and macrophage recruitment and levels of resolution molecules (Co-authorship with Torsten Hoffmann & Inge Lues from Probiodrug AG, Germany) (Summer Frontiers Symposium 2016 ‘Systems Biology of Innate Immunity’)
Specialized proresolving mediators and transcriptomic signatures in bleomycin-induced lung fibrosis (ERS International Congress)
Development of a primary human M1 and M2 macrophage model and phagocytosis evaluation of Candida albicans in the presence of lipoxin A4, resolvin D1 and D5 (Miami Symposium on Inflammation 2016 – Best poster prize)
To be filled soon